These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 36857860)

  • 1. COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses.
    Chen Y; Song W; Li C; Wang J; Liu F; Ye Z; Ren P; Tong Y; Li J; Ou Z; Lee AC; Cai JP; Wong BH; Chan JF; Yuen KY; Zhang AJ; Chu H
    EBioMedicine; 2023 Mar; 89():104485. PubMed ID: 36857860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination.
    Tang J; Zeng C; Cox TM; Li C; Son YM; Cheon IS; Wu Y; Behl S; Taylor JJ; Chakaraborty R; Johnson AJ; Shiavo DN; Utz JP; Reisenauer JS; Midthun DE; Mullon JJ; Edell ES; Alameh MG; Borish L; Teague WG; Kaplan MH; Weissman D; Kern R; Hu H; Vassallo R; Liu SL; Sun J
    Sci Immunol; 2022 Oct; 7(76):eadd4853. PubMed ID: 35857583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
    Ying B; Scheaffer SM; Whitener B; Liang CY; Dmytrenko O; Mackin S; Wu K; Lee D; Avena LE; Chong Z; Case JB; Ma L; Kim TTM; Sein CE; Woods A; Berrueta DM; Chang GY; Stewart-Jones G; Renzi I; Lai YT; Malinowski A; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    Cell; 2022 Apr; 185(9):1572-1587.e11. PubMed ID: 35452622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.
    Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H
    EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
    Rescigno M; Agrati C; Salvarani C; Giannarelli D; Costantini M; Mantovani A; Massafra R; Zinzani PL; Morrone A; Notari S; Matusali G; Pinter GL; Uccelli A; Ciliberto G; Baldanti F; Locatelli F; Silvestris N; Sinno V; Turola E; Lupo-Stanghellini MT; Apolone G;
    Front Immunol; 2023; 14():1104124. PubMed ID: 36776853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors.
    Lu BN; Zhu KL; Cui XM; Yao L; Wang XJ; Wang GL; Duan LJ; Qian A; Ma MJ
    Clin Immunol; 2022 Nov; 244():109103. PubMed ID: 36049602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural Severe Acute Respiratory Syndrome Coronavirus 2 Infection (With or Without Subsequent Coronavirus Disease 2019 [COVID-19] Vaccination) Versus 2-Dose COVID-19 Vaccination.
    Lim SY; Park S; Kim JY; Kim S; Jee Y; Kim SH
    Clin Infect Dis; 2022 Dec; 75(12):2243-2246. PubMed ID: 35686300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination After SARS-CoV-2 Infection Increased Antibody Avidity Against the Omicron Variant Compared to Vaccination Alone.
    LeMaster C; Geanes ES; Fraley ER; Selvarangan R; Bradley T
    J Infect Dis; 2022 Nov; 226(10):1712-1716. PubMed ID: 35714328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
    Zens KD; Llanas-Cornejo D; Menges D; Fehr JS; Münz C; Puhan MA; Frei A
    Int J Infect Dis; 2023 Aug; 133():18-26. PubMed ID: 37149211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
    Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
    mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters.
    Yuan L; Zhu H; Chen P; Zhou M; Ma J; Liu X; Wu K; Chen R; Liu Q; Yu H; Li L; Wang J; Zhang Y; Ge S; Yuan Q; Tang Q; Cheng T; Guan Y; Xia N
    Cell Mol Immunol; 2022 Dec; 19(12):1392-1399. PubMed ID: 36258005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.
    O'Meara TR; Nanishi E; McGrath ME; Barman S; Dong D; Dillen C; Menon M; Seo HS; Dhe-Paganon S; Ernst RK; Levy O; Frieman MB; Dowling DJ
    J Allergy Clin Immunol; 2023 Nov; 152(5):1107-1120.e6. PubMed ID: 37595760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
    Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
    Viruses; 2022 May; 14(5):. PubMed ID: 35632698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.